59.62
-0.07 (-0.12%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Catalent, Inc. | Bullish | Bullish |
Stockmoo Score
|
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Elliott Investment Management L.P. | 30 Jun 2024 | 4,000,000 |
| Hudson Bay Capital Management Lp | 30 Jun 2024 | 3,231,723 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 63.50 (RBC Capital, 6.51%) | Hold |
| Median | 63.25 (6.09%) | |
| Low | 63.00 (Barclays, 5.67%) | Hold |
| Average | 63.25 (6.09%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 57.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 11 Jul 2024 | 63.50 (6.51%) | Hold | 58.07 |
| Barclays | 28 Jun 2024 | 63.00 (5.67%) | Hold | 56.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Aug 2024 | Announcement | Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results |
| 16 Jul 2024 | Announcement | Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |